Zhou X, Berenger E, Shi Y, Shirokova V, Kochetkova E, Becirovic T
EMBO Mol Med. 2025; .
PMID: 40055574
DOI: 10.1038/s44321-025-00210-w.
Swain J, Preeti , Mohanty C, Bajoria A, Patnaik S, Ward Gahlawat A
Discov Oncol. 2025; 16(1):275.
PMID: 40053174
PMC: 11889322.
DOI: 10.1007/s12672-025-01949-x.
Seo R, de Guzman A, Park S, Lee J, Kang S
Cell Death Differ. 2025; .
PMID: 40050422
DOI: 10.1038/s41418-025-01466-y.
Jin R, Neufeld L, McGaha T
Nat Cancer. 2025; 6(2):239-252.
PMID: 39962208
DOI: 10.1038/s43018-025-00909-2.
Shen X, Chen Y, Tang Y, Lu P, Liu M, Mao T
Cell Rep Med. 2025; 6(2):101928.
PMID: 39879992
PMC: 11866519.
DOI: 10.1016/j.xcrm.2025.101928.
Metabolic Reprogramming at the Edge of Redox: Connections Between Metabolic Reprogramming and Cancer Redox State.
Serrano J, Medina M
Int J Mol Sci. 2025; 26(2).
PMID: 39859211
PMC: 11765076.
DOI: 10.3390/ijms26020498.
Bulk and single-cell transcriptome revealed the metabolic heterogeneity in human glioma.
Xiao Y, Zhao M, Wang R, Liu L, Xiang C, Li T
Heliyon. 2025; 11(1):e41241.
PMID: 39844970
PMC: 11750464.
DOI: 10.1016/j.heliyon.2024.e41241.
Metabolism-driven chromatin dynamics: Molecular principles and technological advances.
Sahu V, Lu C
Mol Cell. 2025; 85(2):262-275.
PMID: 39824167
PMC: 11750176.
DOI: 10.1016/j.molcel.2024.12.012.
Autophagy regulator ATG5 preserves cerebellar function by safeguarding its glycolytic activity.
Tutas J, Tolve M, Ozer-Yildiz E, Ickert L, Klein I, Silverman Q
Nat Metab. 2025; 7(2):297-320.
PMID: 39815080
PMC: 11860254.
DOI: 10.1038/s42255-024-01196-4.
Two-component system GrpP/GrpQ promotes pathogenicity of uropathogenic Escherichia coli CFT073 by upregulating type 1 fimbria.
Li X, Pang Y, Jiang L, Liu L, Zhou J, Jin C
Nat Commun. 2025; 16(1):607.
PMID: 39799152
PMC: 11724981.
DOI: 10.1038/s41467-025-55982-z.
The Role of Mitochondrial Solute Carriers SLC25 in Cancer Metabolic Reprogramming: Current Insights and Future Perspectives.
Ahmed A, Iaconisi G, Di Molfetta D, Coppola V, Caponio A, Singh A
Int J Mol Sci. 2025; 26(1.
PMID: 39795950
PMC: 11719790.
DOI: 10.3390/ijms26010092.
Activation of the De Novo Serine Synthesis Pathway and Disruption of Insulin Signaling Induced by Supplemental SeMet in Vitro.
Zhan S, Huang J, Liu Y, Han F, Wang J, Wang Q
Biol Trace Elem Res. 2025; .
PMID: 39789350
DOI: 10.1007/s12011-024-04492-y.
FOXC1-mediated serine metabolism reprogramming enhances colorectal cancer growth and 5-FU resistance under serine restriction.
Chen Z, Xu J, Fang K, Jiang H, Leng Z, Wu H
Cell Commun Signal. 2025; 23(1):13.
PMID: 39773485
PMC: 11708197.
DOI: 10.1186/s12964-024-02016-8.
Supplementation with serine-enriched non-essential amino acids from minimum essential medium promotes blastocyst development of in vitro-fertilized bovine embryos.
Itami N, Hirao Y
J Reprod Dev. 2025; 71(1):55-61.
PMID: 39756999
PMC: 11808307.
DOI: 10.1262/jrd.2024-090.
Machine learning based identification of an amino acid metabolism related signature for predicting prognosis and immune microenvironment in pancreatic cancer.
Liu X, Wang X, Ren J, Fang Y, Gu M, Zhou F
BMC Cancer. 2025; 25(1):6.
PMID: 39754071
PMC: 11697724.
DOI: 10.1186/s12885-024-13374-4.
Limiting serine availability during tumor progression promotes muscle wasting in cancer cachexia.
Pranzini E, Muccillo L, Nesi I, Santi A, Mancini C, Lori G
Cell Death Discov. 2024; 10(1):510.
PMID: 39706853
PMC: 11662032.
DOI: 10.1038/s41420-024-02271-1.
Elucidating the causal relationship between 486 genetically predicted blood metabolites and the risk of gastric cancer: a comprehensive Mendelian randomization analysis.
Qian L, Song J, Zhang X, Qiao Y, Tan Z, Li S
Front Oncol. 2024; 14:1418283.
PMID: 39703854
PMC: 11655336.
DOI: 10.3389/fonc.2024.1418283.
Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.
Gawi Ermi A, Sarkar D
Cancers (Basel). 2024; 16(23).
PMID: 39682130
PMC: 11640171.
DOI: 10.3390/cancers16233944.
Senescence Reprogramming by MTHFD2 Deficiency Facilitates Tumor Progression.
Fang Z, Pei W, Wu Q, Niu T, Dong C, Wu M
J Cancer. 2024; 15(20):6577-6593.
PMID: 39668825
PMC: 11632999.
DOI: 10.7150/jca.99168.
The role of metabolic reprogramming in liver cancer and its clinical perspectives.
Lu M, Wu Y, Xia M, Zhang Y
Front Oncol. 2024; 14:1454161.
PMID: 39610917
PMC: 11602425.
DOI: 10.3389/fonc.2024.1454161.